Breaking News

CGI to Provide Biomarker Testing for Lead H3 Candidate

Will employ oncology-focused menu and biomarker development services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cancer Genetics, Inc. (CGI) has been selected by H3 Biomedicine to provide clinical biomarker services for H3’s lead oncology drug candidate H3B-8800, an orally available selective small molecule being developed as an anticancer agent for the potential treatment of select hematologic cancers. CGI will also support biomarker discovery and development for H3’s early-stage candidates.   H3’s SF3B1 clinical program targets deregulated RNA homeostasis in cancer through RNA splicing modulation...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters